Basic notes on unfractionated and low-molecular-weight heparins;Heparine

Therapeutische Umschau

Volumn 60, Issue 1, 2003, Pages 10-13

  Marbet, G A ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULATION; ARTERY OCCLUSION; BLEEDING; BLOOD CLOTTING; CORONARY ARTERY DILATATION; DRUG ACTIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; GLOMERULUS FILTRATION; HEART SURGERY; HOSPITAL; HUMAN; KIDNEY FUNCTION; PARTIAL THROMBOPLASTIN TIME; PREGNANCY; REVIEW; THROMBIN TIME; THROMBOCYTOPENIA; THROMBOEMBOLISM; UNSTABLE ANGINA PECTORIS;

EID: 0037260799     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-5930.60.1.10     Document Type: Review

References (10)

1. Hirsh J. Heparin. N Engl J Med 1991; 324: 1565-74.
2. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688-98.
3. Olson JD, Arkin CF, Brandt JT, et al. College of American Pathologists Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy. Laboratory Monitoring of Unfractionated Heparin Therapy. Arch Pathol Lab Med 1998; 122: 782-98.
4. Laposata M, Green D, Van Cott E, Barrowcliffe TW, Goodnight SH, Sosolik RC. College of American Pathologists Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy. The clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med 1998; 122: 799-807.
5. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin. Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119: 64-94.
6. Bock SC. Antithrombin III and Heparin Cofactor II. In: Colman RW, Hirsh J, Marder VJ, Clowes HW, George JN, eds. Hemostasis and Thrombosis. Basic Principles & Clinical Practice. Philadelphia: Lippincott Williams & Wilkins, 2001: 321-33.
7. Bendetowicz AV, Béguin S, Caplain H, Hemker AC. Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (Enoxaparin) after subcutaneous injection, comparison with unfractionated heparin - a three way crossover study in human volunteers, Thromb Haemostas 1994; 71: 305-13.
8. Kitchen S, Preston FE. The therapeutic range of heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays. Thromb Haemostas 1996; 75: 734-9.
9. Bussey HI. Problems with monitoring heparin anticoagulation. Pharmacotherapy 1999; 19: 2-5.
10. Smythe MA, Koerber JM. Heparin monitoring: the confusion continues. Pharmacotherapy 1999; 19: 1240-2.